# TERUMO CORP

Summary updated: 2026-10-02T08:46:40.936315Z
Canonical: https://finbar.com/research/companies/terumo

## Overview

Terumo Corporation is a Japan-founded healthcare company that manufactures and sells medical products and equipment. Its four core businesses are Cardiac & Vascular, Medical Care Solutions, Blood & Cell Technologies, and Terumo Organ Technologies, spanning areas such as cardiovascular and interventional devices, hospital and infusion products, blood processing, and organ preservation. The company’s Group Mission is “Contributing to Society through Healthcare”; it was founded in 1921. [1](https://app.finbar.com/go?id=P166501461)[2](https://app.finbar.com/go?id=P166502096)[3](https://app.finbar.com/go?id=T19429072)[4](https://www.terumo.com/about/who-we-are)[5](https://www.terumo.com/about/history/100th/history)

Terumo serves more than 160 countries and regions and reports a workforce of more than 30,000 associates worldwide. For the fiscal year ended March 31, 2026, consolidated revenue was ¥1,131,877 million. Its reported sales span Japan, the Americas, Europe, China, and other Asian markets. [4](https://www.terumo.com/about/who-we-are)[6](https://app.finbar.com/go?id=T19429074)[7](https://app.finbar.com/go?id=T19429134)
[1](https://app.finbar.com/go?id=P166501461)[2](https://app.finbar.com/go?id=P166502096)[3](https://app.finbar.com/go?id=T19429072)[4](https://www.terumo.com/about/who-we-are)[5](https://www.terumo.com/about/history/100th/history)[6](https://app.finbar.com/go?id=T19429074)[7](https://app.finbar.com/go?id=T19429134)[4](https://www.terumo.com/about/who-we-are)[5](https://www.terumo.com/about/history/100th/history)

## Products & services

Terumo’s Cardiac and Vascular products include angiographic guidewires and catheters, introducer sheaths, vascular-closure devices, PTCA balloons, coronary and peripheral stents, and intravascular ultrasound and imaging catheters. Its neurovascular range includes aneurysm coils, stents, intrasaccular devices, embolization systems, aspiration catheters and clot retrievers; named products include the WEB intrasaccular aneurysm device and SOFIA 88 support/aspiration catheter. The company also offers oxygenators and cardiopulmonary-bypass systems, heart-lung machines and ECMO systems, as well as artificial vascular grafts and stent grafts, including the TREO abdominal aortic system. [3](https://app.finbar.com/go?id=T19429072) [8](https://www.terumoneuro.com/products/web-family) [9](https://www.terumoneuro.com/products/sofia-88) [10](https://www.terumo.com/business/cardiovascular) [11](https://www.terumo.com/business/aortic)

Medical Care Solutions products include syringes, infusion and syringe pumps, infusion lines, IV solutions, peritoneal-dialysis fluid, pain-management products and adhesion barriers. Terumo describes its connected pumps as offering drug libraries and hospital-system connectivity. Life Care products include blood-glucose monitoring devices, pen-injector needles, insulin patch pumps, blood-pressure monitors and thermometers; MEDISAFE WITH is a tube-free insulin patch pump operated by remote control. Pharmaceutical Solutions includes contract manufacturing of prefilled syringes and pharmaceutical packaging devices and needles; PLAJEX is a ready-to-fill polymer syringe line. [3](https://app.finbar.com/go?id=T19429072) [12](https://www.terumo.com/business/hospital-care-solutions) [13](https://www.terumo.com/business/life-care-solutions) [14](https://medisafewith.terumo.com/jp/en/) [15](https://www.terumo.com/business/pharmaceutical-solutions) [16](https://www.terumopharmaceuticalsolutions.com/en/products/prefillable-syringes/plajex-syringe-with-staked-needle)

Blood and Cell Technologies offers blood bags, automated blood-processing and component-collection systems, pathogen-reduction systems, centrifugal apheresis systems, cell-expansion systems and plasma-donation systems. Reveos automates whole-blood processing, handling up to four units per run and separating components in one centrifugation cycle. Spectra Optia uses continuous-flow centrifugation and optical detection for therapeutic apheresis, cell processing and collection. Terumo Organ Technologies includes an organ-preservation device; metra, from OrganOx, is a normothermic liver-perfusion system that circulates oxygenated, blood-based perfusate at body temperature during donor-liver transport. [3](https://app.finbar.com/go?id=T19429072) [17](https://www.terumobct.com/en/gl/products-services/global-blood-solutions/global-blood-solutions-products/reveos.html) [18](https://www.terumobct.com/en/gl/products-services/therapeutic-apheresis/therapeutic-apheresis-products--indications--and-protocols/spectra-optia-apheresis-system.html) [19](https://www.terumo.com/business/terumo-organ-technologies) [20](https://www.organox.com/products)

For the fiscal year ended March 31, 2026, revenue was ¥1,131,877 million. Reportable-segment revenue was ¥676,421 million for Cardiac and Vascular (about 59.8% of consolidated revenue), ¥216,138 million for Medical Care Solutions (19.1%), ¥231,037 million for Blood and Cell Technologies (20.4%), and ¥7,985 million for Terumo Organ Technologies (0.7%). The segment total differs slightly from consolidated revenue because of reported revenue adjustments; OrganOx was consolidated from its acquisition on October 29, 2025, so its figure is a partial-year contribution. [21](https://app.finbar.com/go?id=T19428995)
[3](https://app.finbar.com/go?id=T19429072)[21](https://app.finbar.com/go?id=T19428995)[21](https://app.finbar.com/go?id=T19428995)[21](https://app.finbar.com/go?id=T19428995)[21](https://app.finbar.com/go?id=T19428995)[21](https://app.finbar.com/go?id=T19428995)[21](https://app.finbar.com/go?id=T19428995)[21](https://app.finbar.com/go?id=T19428995)[8](https://www.terumoneuro.com/products/web-family)[9](https://www.terumoneuro.com/products/sofia-88)[10](https://www.terumo.com/business/cardiovascular)[11](https://www.terumo.com/business/aortic)[12](https://www.terumo.com/business/hospital-care-solutions)[13](https://www.terumo.com/business/life-care-solutions)[14](https://medisafewith.terumo.com/jp/en/)[15](https://www.terumo.com/business/pharmaceutical-solutions)[16](https://www.terumopharmaceuticalsolutions.com/en/products/prefillable-syringes/plajex-syringe-with-staked-needle)[17](https://www.terumobct.com/en/gl/products-services/global-blood-solutions/global-blood-solutions-products/reveos.html)[18](https://www.terumobct.com/en/gl/products-services/therapeutic-apheresis/therapeutic-apheresis-products--indications--and-protocols/spectra-optia-apheresis-system.html)[19](https://www.terumo.com/business/terumo-organ-technologies)[20](https://www.organox.com/products)

## Geographic presence

For the fiscal year ended March 31, 2026, Terumo reported consolidated revenue of ¥1,131,877 million. Revenue by customer location was ¥443,405 million in the Americas (about 39% of total), ¥242,655 million in Europe (21%), ¥222,603 million in Japan (20%), ¥91,309 million in China (8%), and ¥131,902 million in Asia and other markets (12%). [7](https://app.finbar.com/go?id=T19429134)[2](https://app.finbar.com/go?id=P166502096)

Terumo’s locations directory covers Japan, North America, South America, EMEA, Greater China, and Asia-Pacific. Its corporate headquarters is in Tokyo, and its listed Japanese locations include a Tokyo office and the Shonan Center in Kanagawa. [22](https://www.terumo.com/contact/locations)[23](https://www.terumo.com/contact/locations/japan/tc)[24](https://www.terumo.com/contact/locations/japan)

The company describes product development and manufacturing as concentrated mainly in Japan and the United States, with factories in Asia and other emerging markets more focused on mass production. Its FY2026 report lists significant subsidiaries in Belgium, the United States, China, and Singapore. Terumo reports more than 30,000 associates worldwide, without a regional employee breakdown on the cited company profile. [25](https://www.terumo.com/technology/basic/production)[26](https://app.finbar.com/go?id=T19429162)[4](https://www.terumo.com/about/who-we-are)
[7](https://app.finbar.com/go?id=T19429134)[2](https://app.finbar.com/go?id=P166502096)[26](https://app.finbar.com/go?id=T19429162)[22](https://www.terumo.com/contact/locations)[23](https://www.terumo.com/contact/locations/japan/tc)[24](https://www.terumo.com/contact/locations/japan)[25](https://www.terumo.com/technology/basic/production)[4](https://www.terumo.com/about/who-we-are)

## Business segments

For the fiscal year ended 31 March 2026, Terumo reported four business segments. Cardiac and Vascular Company generated ¥676,421 million, approximately 59.8% of consolidated revenue, with products spanning interventional, neurovascular, cardiovascular and aortic care. Medical Care Solutions Company generated ¥216,138 million (19.1%), focusing on hospital care, life care and pharmaceutical solutions. Blood and Cell Technologies Company generated ¥231,037 million (20.4%), covering blood and cell-processing products and systems. Terumo Organ Technologies generated ¥7,985 million (0.7%), principally from an organ-preservation device. [3](https://app.finbar.com/go?id=T19429072)[6](https://app.finbar.com/go?id=T19429074)

Consolidated revenue was ¥1,131,877 million; reportable-segment revenue totaled ¥1,131,582 million, with the difference recorded as adjustments. Terumo also discloses revenue by geography, including the Americas, Japan, Europe, China, and Asia and others. [6](https://app.finbar.com/go?id=T19429074)[7](https://app.finbar.com/go?id=T19429134)
[3](https://app.finbar.com/go?id=T19429072)[6](https://app.finbar.com/go?id=T19429074)[7](https://app.finbar.com/go?id=T19429134)

## Company history

Terumo was founded in Tokyo on 17 September 1921 by a group of physicians and scientists seeking to produce accurate clinical thermometers in Japan; Dr. Shibasaburo Kitasato was among those associated with the founding effort. Its first clinical thermometer launched in 1922, and the company was renamed Jintan Thermometer Corporation in 1936. [27](https://www.terumo.com/about/history) [28](https://www.terumo.com/newsrelease/detail/20210105/582)

The company expanded beyond thermometers with Japan’s first disposable syringe in 1963 and its first blood bag in 1969, then established affiliates in the United States and Belgium in 1971. It adopted the name Terumo Corporation in 1974 and launched the Capiox II oxygenator in 1982. [27](https://www.terumo.com/about/history) In later decades, acquisitions broadened its medical-device businesses: Vascutek in 2002, MicroVention in 2006, CaridianBCT in 2011, Sequent Medical in 2016, and Bolton Medical in 2017; Vascutek and Bolton Medical were integrated as Terumo Aortic in 2018. [29](https://www.terumo.com/newsrelease/detail/20180423/284) [30](https://www.terumo.com/newsrelease/detail/20220929/5506) [31](https://www.terumo.com/newsrelease/detail/20160614/264) [32](https://www.terumo.com/newsrelease/detail/20170403/248) Terumo marked its centenary in 2021, and Hikaru Samejima became CEO in April 2024, succeeding Shinji Sato. [33](https://www.terumo.com/newsrelease/detail/20210917/642) [34](https://www.terumo.com/system/files/document/2024-02/20240207_E_3.pdf)
[27](https://www.terumo.com/about/history)[28](https://www.terumo.com/newsrelease/detail/20210105/582)[29](https://www.terumo.com/newsrelease/detail/20180423/284)[30](https://www.terumo.com/newsrelease/detail/20220929/5506)[31](https://www.terumo.com/newsrelease/detail/20160614/264)[32](https://www.terumo.com/newsrelease/detail/20170403/248)[33](https://www.terumo.com/newsrelease/detail/20210917/642)[34](https://www.terumo.com/system/files/document/2024-02/20240207_E_3.pdf)[27](https://www.terumo.com/about/history)[28](https://www.terumo.com/newsrelease/detail/20210105/582)[29](https://www.terumo.com/newsrelease/detail/20180423/284)[30](https://www.terumo.com/newsrelease/detail/20220929/5506)[31](https://www.terumo.com/newsrelease/detail/20160614/264)[32](https://www.terumo.com/newsrelease/detail/20170403/248)[33](https://www.terumo.com/newsrelease/detail/20210917/642)[34](https://www.terumo.com/system/files/document/2024-02/20240207_E_3.pdf)

## Sources

1. [TERUMO CORP — Full financial report (2026 Y), p16](https://app.finbar.com/go?id=P166501461)
2. [TERUMO CORP — Full financial report (2026 Y), p61](https://app.finbar.com/go?id=P166502096)
3. [TERUMO CORP — Full financial report (2026 Y), p31](https://app.finbar.com/go?id=T19429072)
4. [www.terumo.com](https://www.terumo.com/about/who-we-are)
5. [www.terumo.com](https://www.terumo.com/about/history/100th/history)
6. [TERUMO CORP — Full financial report (2026 Y), p33](https://app.finbar.com/go?id=T19429074)
7. [TERUMO CORP — Full financial report (2026 Y), p62](https://app.finbar.com/go?id=T19429134)
8. [www.terumoneuro.com](https://www.terumoneuro.com/products/web-family)
9. [www.terumoneuro.com](https://www.terumoneuro.com/products/sofia-88)
10. [www.terumo.com](https://www.terumo.com/business/cardiovascular)
11. [www.terumo.com](https://www.terumo.com/business/aortic)
12. [www.terumo.com](https://www.terumo.com/business/hospital-care-solutions)
13. [www.terumo.com](https://www.terumo.com/business/life-care-solutions)
14. [medisafewith.terumo.com](https://medisafewith.terumo.com/jp/en/)
15. [www.terumo.com](https://www.terumo.com/business/pharmaceutical-solutions)
16. [www.terumopharmaceuticalsolutions.com](https://www.terumopharmaceuticalsolutions.com/en/products/prefillable-syringes/plajex-syringe-with-staked-needle)
17. [www.terumobct.com](https://www.terumobct.com/en/gl/products-services/global-blood-solutions/global-blood-solutions-products/reveos.html)
18. [www.terumobct.com](https://www.terumobct.com/en/gl/products-services/therapeutic-apheresis/therapeutic-apheresis-products--indications--and-protocols/spectra-optia-apheresis-system.html)
19. [www.terumo.com](https://www.terumo.com/business/terumo-organ-technologies)
20. [www.organox.com](https://www.organox.com/products)
21. [TERUMO CORP — Additional data (2026 Y), p3](https://app.finbar.com/go?id=T19428995)
22. [www.terumo.com](https://www.terumo.com/contact/locations)
23. [www.terumo.com](https://www.terumo.com/contact/locations/japan/tc)
24. [www.terumo.com](https://www.terumo.com/contact/locations/japan)
25. [www.terumo.com](https://www.terumo.com/technology/basic/production)
26. [TERUMO CORP — Full financial report (2026 Y), p76](https://app.finbar.com/go?id=T19429162)
27. [www.terumo.com](https://www.terumo.com/about/history)
28. [www.terumo.com](https://www.terumo.com/newsrelease/detail/20210105/582)
29. [www.terumo.com](https://www.terumo.com/newsrelease/detail/20180423/284)
30. [www.terumo.com](https://www.terumo.com/newsrelease/detail/20220929/5506)
31. [www.terumo.com](https://www.terumo.com/newsrelease/detail/20160614/264)
32. [www.terumo.com](https://www.terumo.com/newsrelease/detail/20170403/248)
33. [www.terumo.com](https://www.terumo.com/newsrelease/detail/20210917/642)
34. [www.terumo.com](https://www.terumo.com/system/files/document/2024-02/20240207_E_3.pdf)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.